Brian DeRubertis, MD, FACS
@derubertisMD
Followers
257
Following
3
Media
0
Statuses
8
Chief of the Division of Vascular & Endovascular Surgery at New York Presbyterian-Weill Cornell Medicine
New York, NY
Joined September 2015
#VIVA24: Along with Lorenzo Patrone who is still in transit to Las Vegas, @sternvascular receives the 2024 VCA Award from @VIVAPhysicians. The accolade is given to young physician-leaders for vascular career advancement.
1
8
42
The first patient has been successfully treated with our Esprit BTK Everolimus Eluting Resorbable Scaffold System, pioneering a new standard of care in BTK treatment. Thanks @PK_MountSinai and team for your commitment to your patients. Safety Info: https://t.co/twivNLQTJC
0
9
47
We followed a great morning with a wonderful afternoon watching the first Esprit BTK commercial case at Columbia performed by @sahilparikhmd @AbbottCardio #ProudtobeAbbott
5
7
62
Spending the morning with @derubertisMD observing the first commercial Esprit BTK case at Cornell is a great way to start the day. We are excited about what this therapy is bringing to patients. @AbbottCardio #ProudtobeAbbott
2
3
30
Abbott Begins LIFE-BTK Trial to Evaluate Esprit BTK Drug-Eluting Resorbable Scaffold to Treat CLI | @AbbottNews
https://t.co/uAhmG8eA14
evtoday.com
September 3, 2020—Abbott announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company’s new
0
2
7
Important time for patients suffering the threat of limb loss. Looking forward to the exciting work we have ahead of us in helping to evaluate this technology for our patients. @RamonVarcoeMD @sahilparikhmd
Breaking at #VEITH2019: Announcing the LIFE-BTK pivotal IDE clinical trial to evaluate the safety & effectiveness of ESPRIT BTK, a new everolimus eluting bioresorbable scaffold intended for treating critical limb ischemia! Read about the #innovativetech: https://t.co/dPOl4xhRvx
0
3
6